You are here:
| Reference : Serum zinc and copper as prognostic factors in acute nonlymphocytic leukemia. |
| Scientific journals : Article | |||
| Human health sciences : Hematology | |||
| http://hdl.handle.net/2268/6666 | |||
| Serum zinc and copper as prognostic factors in acute nonlymphocytic leukemia. | |
| English | |
Beguin, Yves  [Centre Hospitalier Universitaire de Liège - CHU > > Hématologie clinique >] | |
| Bury, J. [> > > >] | |
| Delbrouck, J. M. [> > > >] | |
| Fillet, Georges [Centre Hospitalier Universitaire de Liège - CHU > > Hématologie clinique >] | |
| Robaye, G. [> > > >] | |
| Roelandts, I. [> > > >] | |
| Weber, Géraldine [Centre Hospitalier Universitaire de Liège - CHU > > Médecine de l'appareil locomoteur >] | |
| 1987 | |
| Haematology and Blood Transfusion | |
| 30 | |
| 380-4 | |
| International | |
| 0171-7111 | |
| [en] Acute Disease ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Copper/blood ; Cytarabine/administration & dosage ; Daunorubicin/administration & dosage ; Female ; Humans ; Leukemia/blood/drug therapy ; Male ; Middle Aged ; Prognosis ; Remission Induction ; Vincristine/administration & dosage ; Zinc/blood | |
| [en] A total of 44 patients were treated with intensive induction chemotherapy for acute nonlymphocytic leukemia (ANLL). A complete remission (CR) was obtained in 29/44 (66%) patients. Serum zinc (Zn) and copper (Cu) were studied as possible prognostic factors in the determination of the chance of a patient attaining remission. Pretreatment Zn was higher in patients attaining a remission (0.99 +/- 0.05 microgram/ml) than in patients failing to attain a CR (0.78 +/- 0.06 microgram/ml) (P = 0.0216). There was no further difference between the two groups during aplasia. However, when response to treatment was evaluated about day 28, the difference reappeared: 1.06 +/- 0.05 microgram/ml for CR patients vs 0.77 +/- 0.07 microgram/ml for failures (p = 0.0012). Pretreatment Cu was higher in responding (1.44 +/- 0.07 microgram/ml) than in nonresponding (1.06 +/- 0.05 microgram/ml) patients (p = 0.0002). The difference between the two groups remained highly significant at days 7, 14, 21, and 28. At the time of response evaluation, the values were 1.46 +/- 0.05 microgram/ml for CR patients vs 1.19 +/- 0.08 microgram/ml for non-CR patients (P = 0.0070). We conclude that the measurement of serum Zn and Cu may be helpful in the prediction of response to chemotherapy in patients treated for ANLL. | |
| http://hdl.handle.net/2268/6666 |
There is no file associated with this reference.
All documents in ORBi are protected by a user license.
